{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:00:30Z","timestamp":1772020830784,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1007\/s11095-007-9470-6","type":"journal-article","created":{"date-parts":[[2008,1,30]],"date-time":"2008-01-30T23:04:17Z","timestamp":1201734257000},"page":"1052-1062","source":"Crossref","is-referenced-by-count":29,"title":["Buprederm\u2122, a New Transdermal Delivery System of Buprenorphine: Pharmacokinetic, Efficacy and Skin Irritancy Studies"],"prefix":"10.1007","volume":"25","author":[{"given":"In","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jindeog","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Hoon","family":"In","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Wei","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bumchan","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-Ok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,2,1]]},"reference":[{"issue":"3","key":"9470_CR1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1017\/S0140525X97271487","volume":"20","author":"H. Blumberg","year":"1997","unstructured":"H. Blumberg, U. Hoffmann, M. Mohadjer, and R. Scheremet. Sympathetic nervous system and pain: a clinical reappraisal. Behav. Brain Sci. 20(3):426\u2013434 (1997).","journal-title":"Behav Brain Sci"},{"key":"9470_CR2","first-page":"47","volume":"8","author":"D. A. Drossman","year":"1995","unstructured":"D. A. Drossman, F. H. Creed, G. A. Fava, K. W. Olden, D. L. Patrick, and B. B. Toner. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterol. Int. 8:47\u201390 (1995).","journal-title":"Gastroenterol Int"},{"key":"9470_CR3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7326\/0003-4819-133-2-200007180-00013","volume":"133","author":"J. Jailwala","year":"2000","unstructured":"J. Jailwala, T.F. Imperiale, and K. Kroenke. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann. Intern. Med. 133:135\u2013147 (2000).","journal-title":"Ann Intern Med"},{"issue":"12","key":"9470_CR4","first-page":"1539","volume":"51","author":"K. S. Lewis","year":"1994","unstructured":"K. S. Lewis, K. J. Wipple, K. A. Michael, and E. J. Quebbeman. Effect of analgesic treatment on the physiological consequences of acute pain. Am. J. Hosp. Pharm. 51(12):1539\u20131554 (1994).","journal-title":"Am J Hosp Pharm"},{"issue":"4","key":"9470_CR5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00001503-200108000-00007","volume":"14","author":"G. P. Joshi","year":"2001","unstructured":"G. P. Joshi, and P. F. White. Management of acute and postoperative pain. Curr. Opin. Anaesthesiol. 14(4):417\u2013421 (2001).","journal-title":"Curr Opin Anaesthesiol"},{"issue":"3","key":"9470_CR6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00001503-200406000-00010","volume":"17","author":"S. Suresh","year":"2004","unstructured":"S. Suresh. Chronic and cancer pain management. Curr. Opin. Anaesthesiol. 17(3):253\u2013259 (2004).","journal-title":"Curr Opin Anaesthesiol"},{"issue":"5","key":"9470_CR7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00001503-200210000-00014","volume":"15","author":"I. Gralow","year":"2002","unstructured":"I. Gralow. Cancer pain: an update of pharmacological approaches in pain therapy. Curr. Opin. Anaesthesiol. 15(5):555\u2013561 (2002).","journal-title":"Curr Opin Anaesthesiol"},{"issue":"3","key":"9470_CR8","first-page":"163","volume":"4","author":"S. Perrot","year":"2006","unstructured":"S. Perrot. Management strategies for the treatment of non malignant chronic pain in the elderly. Psychol. Neuropsychiatr. Vieil. 4(3):163\u2013170 (2006).","journal-title":"Psychol Neuropsychiatr Vieil"},{"issue":"Suppl 2","key":"9470_CR9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2165\/00003495-199700532-00005","volume":"53","author":"L. Brasseur","year":"1997","unstructured":"L. Brasseur. Review of current pharmacologic treatment of pain. Drugs 53(Suppl 2):10\u201317 (1997)(Review).","journal-title":"Drugs"},{"issue":"1","key":"9470_CR10","first-page":"34","volume":"53","author":"M. Krsiak","year":"2004","unstructured":"M. Krsiak. How to advance in treating pain with opioids: less myths\u2014less pain. Cesk Fysiol. 53(1):34\u201338 (2004)(Review).","journal-title":"Cesk Fysiol"},{"issue":"23","key":"9470_CR11","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.2165\/00003495-200464230-00002","volume":"64","author":"T. L. Schaer","year":"2004","unstructured":"T. L. Schaer. Practice guidelines for transdermal opioids in malignant pain. Drugs 64(23):2629\u20132638 (2004)(Review).","journal-title":"Drugs"},{"issue":"3","key":"9470_CR12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0304-3959(97)00040-7","volume":"72","author":"P. R. Picard","year":"1997","unstructured":"P. R. Picard, M. R. Tramer, H. J. McQuay, and R. A. Moore. Analgesic efficacy of peripheral opioids (all except intra-articular): a qualitative systematic review of randomised controlled trials. Pain 72(3):309\u201318 (1997)(Review).","journal-title":"Pain"},{"issue":"5","key":"9470_CR13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00001503-199810000-00019","volume":"11","author":"S. Grond","year":"1998","unstructured":"S. Grond, and T. Meuser. Weak opioids\u2014an educational substitute for morphine? Curr. Opin. Anaesthesiol. 11(5):559\u2013565 (1998).","journal-title":"Curr Opin Anaesthesiol"},{"issue":"1","key":"9470_CR14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00004714-199602000-00010","volume":"16","author":"E. C. Strain","year":"1996","unstructured":"E. C. Strain, M. L. Stitzer, I. A. Liebson, and G. E. Bigelow. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. J. Clin. Psychopharmacol. 16(1):58\u201367 (1996).","journal-title":"J Clin Psychopharmacol"},{"key":"9470_CR15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/jps.2600830204","volume":"83","author":"E. C. Strain","year":"1994","unstructured":"E. C. Strain, M. L. Stitzer, I. A. Liebson, and G. E. Bigelow. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am. J. Pharm. Sci. 83:126\u2013130 (1994).","journal-title":"Am J Pharm Sci"},{"key":"9470_CR16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","volume":"35","author":"D. R. Jasinski","year":"1978","unstructured":"D. R. Jasinski, J. S. Pevnick, and J. D. Griffith. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psychiatry. 35:501\u2013516 (1978).","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"9470_CR17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1300\/J069v25n01_04","volume":"25","author":"E. Gorman","year":"2006","unstructured":"E. Gorman. Fentanyl abuse and dependence: further evidence for second hand exposure hypothesis. J. Addict. Dis. 25(1):15\u201321 (2006).","journal-title":"J Addict Dis"},{"issue":"1","key":"9470_CR18","first-page":"61","volume":"5","author":"C. Rossano","year":"1982","unstructured":"C. Rossano, L.F. De Luca, V. Firetto, and F. Fossi. Activity and tolerability of buprenorphine after parenteral and sublingual administration. Clin. Ther. 5(1):61\u201368 (1982).","journal-title":"Clin Ther"},{"issue":"3\u20134","key":"9470_CR19","first-page":"93","volume":"77","author":"D. Dini","year":"1986","unstructured":"D. Dini, T. Fassio, A. Gottlieb, and M. Gini. Controlled study of the analgesic effect and tolerability of buprenorphine in cancer patients. Minerva Med. 77(3\u20134):93\u2013104 (1986).","journal-title":"Minerva Med"},{"key":"9470_CR20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1476-5381.1977.tb07532.x","volume":"60","author":"A. Cowan","year":"1977","unstructured":"A. Cowan, J. W. Lewis, and I. R. Macfarlane. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 60:537\u2013545 (1977).","journal-title":"Br J Pharmacol"},{"key":"9470_CR21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1476-5381.1977.tb07533.x","volume":"60","author":"A. Cowan","year":"1977","unstructured":"A. Cowan, J. C. Doxey, and E. J. R. Harry. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br. J. Pharmacol. 60:547\u2013554 (1977).","journal-title":"Br J Pharmacol"},{"key":"9470_CR22","first-page":"31","volume-title":"Buprnorphine: Combatting Drug Abuse with a Unique Opioid","author":"A. Cowan","year":"1995","unstructured":"A. Cowan. Update on the general pharmacology of buprenorphine. In A. Cowan, and J. W. Lewis (eds.), Buprnorphine: Combatting Drug Abuse with a Unique Opioid. Wiley-Liss, New York, 1995, pp. 31\u201347."},{"issue":"5","key":"9470_CR23","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.annemergmed.2003.11.006","volume":"43","author":"K. A. Sporer","year":"2004","unstructured":"K. A. Sporer. Buprenorphine: a primer for emergency physicians. Ann. Emerg. Med. 43(5):580\u2013584 (2004)(Review).","journal-title":"Ann Emerg Med"},{"key":"9470_CR24","first-page":"3","volume":"133","author":"A. Cowan","year":"2003","unstructured":"A. Cowan. Buprenorphine: new pharmacological aspects. Int. J. Clin. Pract. Suppl. 133:3\u20138 (2003).","journal-title":"Int J Clin Pract Suppl"},{"key":"9470_CR25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0378-5173(96)85198-2","volume":"132","author":"I. R. Wilding","year":"1996","unstructured":"I. R. Wilding, S. S. Davis, G. H. Rimoy, P. Rubin, T. Kurihar-Bergstrom, V. Tipnis, B. Berner, and J. Nightingale. Pharmacokinetic evaluation of transdermal buprenorphine in man. Int. J. Pharm. 132:81\u201387 (1996).","journal-title":"Int J Pharm"},{"issue":"19","key":"9470_CR26","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2165\/00003495-200363190-00003","volume":"63","author":"H. C. Evans","year":"2003","unstructured":"H. C. Evans, and S. E. Easthope. Transdermal buprenorphine. Drugs 63(19):1999\u20132010 (2003).","journal-title":"Drugs"},{"issue":"3","key":"9470_CR27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1586\/14737175.5.3.315","volume":"5","author":"R. Sittl","year":"2005","unstructured":"R. Sittl. Transdermal buprenorphine in the treatment of chronic pain. Expert Rev. Neurother. 5(3):315\u2013323 (2005).","journal-title":"Expert Rev. Neurother."},{"issue":"11","key":"9470_CR28","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.clinthera.2004.11.008","volume":"26","author":"J. Sorge","year":"2004","unstructured":"J. Sorge, and R. Sittl. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther. 26(11):1808\u20131820 (2004).","journal-title":"Clin Ther"},{"key":"9470_CR29","first-page":"9","volume":"133","author":"K. Budd","year":"2003","unstructured":"K. Budd. Buprenorphine and the transdermal system: the ideal match in pain management. Int. J. Clin. Pract. Suppl. 133:9\u201314 (2003).","journal-title":"Int J Clin Pract Suppl"},{"key":"9470_CR30","first-page":"15","volume":"133","author":"L. Radbruch","year":"2003","unstructured":"L. Radbruch. Buprenorphine TDS: the clinical development-rationale and results. Int. J. Clin. Pract. Suppl. 133:15\u201318 (2003).","journal-title":"Int J Clin Pract Suppl"},{"issue":"3","key":"9470_CR31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jpainsymman.2004.07.005","volume":"29","author":"R. E. Johnson","year":"2005","unstructured":"R. E. Johnson, P. J. Fudala, and R. Payne. Buprenorphine: considerations for pain management. J. Pain Symptom Manage 29(3):297\u2013326 (2005)(Review).","journal-title":"J Pain Symptom Manage"},{"issue":"19","key":"9470_CR32","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2165\/00003495-200363190-00003","volume":"63","author":"H. C. Evans","year":"2003","unstructured":"H. C. Evans, and S. E. Easthope. Transdermal buprenorphine. Drugs 63(19):1999\u20132010 (2003).","journal-title":"Drugs"},{"key":"9470_CR33","unstructured":"KFDA. Test Guidelines for Safety Evaluation of Drugs. KFDA Notification. No. 1999-61 (1999)."},{"issue":"3","key":"9470_CR34","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1258\/002367702320162423","volume":"36","author":"J. V. Roughan","year":"2002","unstructured":"J. V. Roughan, and P. A. Flecknell. Buprenorphine: a reappraisal of its antinociceptive effects and therapeutic use in alleviating post-operative pain in animals. Lab. Animals 36(3):322\u2013343 (2002).","journal-title":"Lab Animals"},{"key":"9470_CR35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0006-8993(96)01069-4","volume":"744","author":"C. G. Pick","year":"1997","unstructured":"C. G. Pick, Y. Peter, S. Schreiber, and R. Weizman. Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with \u03ba3 analgesia. Brain Res. 744:41\u201346 (1997).","journal-title":"Brain Res"},{"key":"9470_CR36","unstructured":"W. A. Ritschel, and G. L. Kearns. Volume of distribution and distribution coefficient. In: Handbook of Basic Pharmacokinetics: Concepts and Applications, American Pharmaceutical Association, Washington DC, pp 178\u2013188."},{"key":"9470_CR37","first-page":"24","volume":"17","author":"P. A. Flecknell","year":"1990","unstructured":"P. A. Flecknell, and J. H. Liles. Assessment of the analgesic action of opioid agonist\u2013antagonists in the rabbit. J. Ass. Vet. Anaesth. 17:24\u201329 (1990).","journal-title":"J Ass Vet Anaesth"},{"key":"9470_CR38","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0378-4347(01)00029-9","volume":"754","author":"A. Polettini","year":"2001","unstructured":"A. Polettini, and M. A. Huestis. Simultaneous determination of buprenorphine, norbuprenorphine and buprenorphine-glucuronide in plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 754:447\u2013459 (2001).","journal-title":"J Chromatogr B"},{"key":"9470_CR39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0939-6411(00)00135-1","volume":"51","author":"S. Gopal","year":"2001","unstructured":"S. Gopal, T. B. Tzeng, and A. Cowan. Development and validation of a sensitive analytical method for the simultaneous determination of buprenorphine and norbuprenorphine in human plasma. Eur. J. Pharmacol. 51:147\u2013151 (2001).","journal-title":"Eur J Pharmacol"},{"key":"9470_CR40","first-page":"2","volume":"22","author":"M. Ohtani","year":"1985","unstructured":"M. Ohtani, H. Kotaki, K. Nishitateno, Y. Sawada, and T. Iga. Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats. Drug Metab. Dispos. 22:2\u20137 (1985).","journal-title":"Drug Metab Dispos"},{"key":"9470_CR41","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0731-7085(03)00169-9","volume":"32","author":"A. Ceccato","year":"2003","unstructured":"A. Ceccato, R. Klinkenberg, P. Hubert, and B. Streel. Sensitive determination of buprenorphine and its N-dealkylated metabolite norbuprenorphine in human plasma by liquid chromatography coupled to tandem mass spectrometry. J. Pharm. Biomed. Anal. 32:619\u2013631 (2003).","journal-title":"J Pharm Biomed Anal"},{"key":"9470_CR42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/abio.2002.5673","volume":"306","author":"D. E. Moody","year":"2002","unstructured":"D. E. Moody, M. H. Slawson, E. C. Strain, J. D. Laycock, A. C. Spanbauer, and R. L. Foltz. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine and a coformulant, Naloxone, that is suitable for in vivo and in vitro metabolism. Anal. Biochem. 306:31\u201339 (2002).","journal-title":"Anal Biochem"},{"issue":"1\u20133","key":"9470_CR43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2006.07.027","volume":"546","author":"G. P. Hernandez-Delgadillo","year":"2006","unstructured":"G. P. Hernandez-Delgadillo, and S. L. Cruz. Endogenous opioids are involved in morphine and dipyrone analgesic potentiation in the tail flick test in rats. Eur. J. Pharmacol. 546(1\u20133):54\u201359 (2006).","journal-title":"Eur J Pharmacol"},{"key":"9470_CR44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1476-5381.1968.tb00973.x","volume":"32","author":"H. O. J. Collier","year":"1968","unstructured":"H. O. J. Collier, L. C. Dinneen, A. Chistine, A. Johnson, and C. Schneider. The abdominal constriction response and its suppression by analgesic drugs in the mouse. Br. J. Pharmacol. Chemother. 32:295\u2013310 (1968).","journal-title":"Br J Pharmacol Chemother"},{"key":"9470_CR45","first-page":"377","volume":"82","author":"J. H. Draize","year":"1994","unstructured":"J. H. Draize, G. Woodand, and H. O. Calvery. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharmacol. Exp. Ther. 82:377\u2013390 (1994).","journal-title":"J Pharmacol Exp Ther"},{"issue":"19","key":"9470_CR46","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2165\/00003495-200363190-00005","volume":"63","author":"R. Sittl","year":"2003","unstructured":"R. Sittl. Buprenorphine transdermal patch: clinical expert report. Germany: Grunenthat GmbH 2000\/Hannah C. Evans & Stephanie E. Easthope 2003, Transdermal Buprenorphine. Drug 63(19):1999\u20132010 (2003).","journal-title":"Drug"},{"issue":"10","key":"9470_CR47","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/jps.2600741008","volume":"74","author":"R. L. Bronaugh","year":"1985","unstructured":"R. L. Bronaugh, and R. F. Stewart. Methods for in vitro percutaneous absorption studies V: Permeation through damaged skin. J. Pharm. Sci. 74(10):1062\u20131066 (1985).","journal-title":"J Pharm Sci"},{"key":"9470_CR48","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/jps.2600740117","volume":"74","author":"R. L. Bronaugh","year":"1985","unstructured":"R. L. Bronaugh, and R. F. Stewart. Methods for in vitro percutaneous absorption studies IV: the flow-through diffusion cell. J. Pharm. Sci. 74:64\u201367 (1985).","journal-title":"J Pharm Sci"},{"issue":"4","key":"9470_CR49","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/03639048309044692","volume":"9","author":"A. M. Kligman","year":"1983","unstructured":"A. M. Kligman. A biological brief on percutaneous absorption. Drug Dev. Ind. Pharm. 9(4):521\u2013560 (1983).","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"9470_CR50","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1382-6689(00)00035-1","volume":"8","author":"P. Sartorelli","year":"2000","unstructured":"P. Sartorelli, H. R. Andersen, J. Angerer, J. Corish, H. Drexler, T. G\u00f6en, P. Griffin, S. A. M. Hotchkiss, F. Larese, L. Montomoli, J. Perkins, M. Schmelz, J. van de Sandt, and F. Williams. Percutaneous penetration studies for risk assessment. Environ. Toxicol. Pharmacol. 8(2):133\u2013152 (2000).","journal-title":"Environ Toxicol Pharmacol"},{"key":"9470_CR51","unstructured":"ECETOC (1993) In: Percutaneous Absorption, European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels, Monograph Nr. 20, 1\u201380."},{"key":"9470_CR52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0168-3659(85)90035-5","volume":"2","author":"W. R Good","year":"1985","unstructured":"W. R Good, M. S. Powers, P. Campbell, and L. Schenkel. A new transdermal delivery system for estradiol. J. Control. Release 2:89\u201397 (1985).","journal-title":"J Control Release"},{"key":"9470_CR53","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/clpt.1991.138","volume":"50","author":"N. L. Benowitz","year":"1991","unstructured":"N. L. Benowitz, K. Chan, C. P. Denaro, and P. Jacob III. Stable isotope method for studying transdermal drug absorption: the nicotine patch. Clin. Pharmacol. Ther. 50:286\u2013293 (1991).","journal-title":"Clin Pharmacol Ther"},{"key":"9470_CR54","first-page":"505","volume":"272","author":"M. Ohtani","year":"1995","unstructured":"M. Ohtani, H. Kotaki, Y. Sawada, and T. Iga. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J. Pharmacol. Exp. Ther. 272:505\u2013510 (1995).","journal-title":"J Pharmacol Exp Ther"},{"key":"9470_CR55","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1124\/jpet.104.082560","volume":"313","author":"A. Yassen","year":"2005","unstructured":"A. Yassen, E. Olofsen, A. Dahan, and M. Danhof. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentabyl in rats: role of receptor equilibration kinetics. J. Pharmacol. Exp. Ther. 313:1136\u20131149 (2005).","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"9470_CR56","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/jcbfm.1991.102","volume":"11","author":"R. Kawai","year":"1991","unstructured":"R. Kawai, R.E. Carson, B. Dunn, A. H. Newman, K. C. Rice, and R. G. Blasberg. Regional brain measurement of Bmax and KD with the opiate antagonist cyclofoxy: equilibrium studies in the conscious rat. J. Cereb. Blood Flow Metab. 11(4):529\u2013544 (1991).","journal-title":"J Cereb Blood Flow Metab"},{"key":"9470_CR57","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1359-6446(00)01632-9","volume":"6","author":"H. Kusuhara","year":"2001","unstructured":"H. Kusuhara, and Y. Sugiyama. Efflux transport systems for drugs at the blood\u2013brain barrier and blood\u2013cerebrospinal fluid barrier (Part 1). Drug Discov. Today 6:150\u2013156 (2001).","journal-title":"Drug Discov Today"},{"key":"9470_CR58","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0022-3565(24)38239-4","volume":"289","author":"T. K. Henthorn","year":"1999","unstructured":"T. K. Henthorn, Y. Liu, M. Mahapatro, and K. Y. Ng. Active transport of fentanyl by the blood\u2013brain barrier. J. Pharmacol. Exp. Ther. 289:1084\u20131089 (1999).","journal-title":"J Pharmacol Exp Ther"},{"key":"9470_CR59","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1097\/00000542-200005000-00030","volume":"92","author":"S. J. Thompson","year":"2000","unstructured":"S. J. Thompson, K. Koszdin, and C. M. Bernards. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 92:1392\u20131399 (2000).","journal-title":"Anesthesiology"},{"key":"9470_CR60","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1211\/0022357022782","volume":"56","author":"M. Rodriguez","year":"2004","unstructured":"M. Rodriguez, I. Ortega, I. Soengas, E. Suarez, J. C. Lukas, and R. Calvo. Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. J. Pharm. Pharmacol. 56:367\u2013374 (2004).","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"9470_CR61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/10611860601141606","volume":"15","author":"T. Suzuki","year":"2007","unstructured":"T. Suzuki, C. Zaima, Y. Moriki, T. Fukami, and K. Tomono. P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood\u2013brain barrier. J. Drug Target. 15(1):67\u201374 (2007).","journal-title":"J Drug Target"},{"key":"9470_CR62","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF01959410","volume":"11","author":"J. W. Wiechers","year":"1989","unstructured":"J. W. Wiechers. The barrier function of the skin in relation to percutaneous absorption of drugs. Pharm. Weekbl. 11:185\u2013198 (1989).","journal-title":"Pharm Weekbl"},{"key":"9470_CR63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0378-5173(80)90054-X","volume":"7","author":"R. C. Wester","year":"1980","unstructured":"R. C. Wester, and P. K. Noonan. Relevance of animal models for percutaneous absorption. Int. J. Pharm. 7:99\u2013110 (1980).","journal-title":"Int J Pharm"},{"issue":"5","key":"9470_CR64","first-page":"335","volume":"19","author":"R. Panchagnula","year":"1997","unstructured":"R. Panchagnula, K. Stemmer, and W. A. Ritschel. Animal models for transdermal drug delivery. Methods Find. Exp. Clin. Pharmacol. 19(5):335\u2013341 (1997).","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"9470_CR65","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1440-1681.2001.03418.x","volume":"28","author":"S. L. Borgland","year":"2001","unstructured":"S. L. Borgland. Acute opioid receptor desensitization and tolerance: is there a link? Clin. Exp. Pharmacol. Physiol. 28:147\u2013154 (2001).","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"9470_CR66","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.brainres.2005.06.027","volume":"1052","author":"D. Debruyne","year":"2005","unstructured":"D. Debruyne, T. Quentin, G. Poisnel, V. Lelong-Boulouard, L. Barre, and A. Coquerel. Acute and chronic administration of clorazepate modifies the cell surface regulation of \u03bc-opioid receptors induced by buprenorphine in specific regions of the rat brain. Brain Res. 1052:222\u2013231 (2005).","journal-title":"Brain Res"},{"key":"9470_CR67","first-page":"3","volume":"133","author":"A. Cowan","year":"2003","unstructured":"A. Cowan. Buprenorphine: new pharmacological aspects. Int. J. Clin. Pract. Suppl 133:3\u20138 (2003).","journal-title":"Int J Clin Pract Suppl"},{"key":"9470_CR68","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2004.11.052","volume":"507","author":"T. Christoph","year":"2005","unstructured":"T. Christoph, B. Kogel, K. Schiene, M. Meen, J. De Vry, and E. Friderichs. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur. J. Pharmacol 507:87\u201398 (2005).","journal-title":"Eur J Pharmacol"},{"key":"9470_CR69","unstructured":"L. Grumbach. The prediction of analgesic activity in man by animal testing. In: R. S. Knighton, P. R. Dumke (eds.), Pain, 15th International Symposium, Detroit, 1964. Little Brown, Boston, 1996, pp. 163\u2013182."},{"issue":"4 Supplement","key":"9470_CR70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1682\/JRRD.2003.08.0041","volume":"40","author":"M. Eaton","year":"2003","unstructured":"M. Eaton. Common animal models for spasticity and pain. J. Rehabil. Res. Dev. 40(4) Supplement:41\u201354 (2003).","journal-title":"J Rehabil Res & Dev"},{"key":"9470_CR71","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0306-3623(91)90452-C","volume":"22","author":"I. Lizasoain","year":"1991","unstructured":"I. Lizasoain. Buprenorphine: bell-shaped dose response curve for its antagonist effects. Gen. Pharmacol. 22 297\u2013300 (1991).","journal-title":"Gen Pharmacol"},{"issue":"32","key":"9470_CR72","doi-asserted-by":"crossref","first-page":"10331","DOI":"10.1523\/JNEUROSCI.23-32-10331.2003","volume":"23","author":"K. Lutfy","year":"2003","unstructured":"K. Lutfy, S. Eitan, C. D. Bryant, Y. C. Yang, N. Saliminejad, W. Walwyn, B. L. Kieffer, H. Takeshima, and F. I. Carroll. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J. Neurosci. 23(32):10331\u201310337 (2003).","journal-title":"J Neurosci"},{"key":"9470_CR73","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0091-3057(97)00336-5","volume":"59","author":"I. Korzeniewska-Rybicka","year":"1998","unstructured":"I. Korzeniewska-Rybicka, and A. Plaznik. Analgesic effects of antidepressant drugs. Pharmacol. Biochem. Behav. 59:331\u20138 (1998).","journal-title":"Pharmacol Biochem Behav"},{"key":"9470_CR74","first-page":"357","volume":"32","author":"S. W. Hajare","year":"2000","unstructured":"S. W. Hajare, S. Chandra, S.K. Tandon, J. Sarma, J. Lal, and A. G. Telang. Analgesic and antipyretic activities of Dalbergia Sissoo leaves. Indian J. Pharmacol. 32:357\u201360 (2000).","journal-title":"Indian J Pharmacol"},{"key":"9470_CR75","first-page":"271","volume":"30","author":"K. D. Effraim","year":"1998","unstructured":"K. D. Effraim, U. A. Osunkwo, P. Onyeyilli, and A. Ngulde. Preliminary investigation of possible antinociceptive activity of aqueous leaf extract Ziziphus spina Christi (Linn). Indian J. Pharmacol. 30:271\u2013272 (1998).","journal-title":"Indian J Pharmacol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-007-9470-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-007-9470-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-007-9470-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T13:33:55Z","timestamp":1737898435000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-007-9470-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,1]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["9470"],"URL":"https:\/\/doi.org\/10.1007\/s11095-007-9470-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,1]]}}}